UA118192C2 - ANTI-VIRUS PHARMACEUTICAL COMPOSITION - Google Patents

ANTI-VIRUS PHARMACEUTICAL COMPOSITION

Info

Publication number
UA118192C2
UA118192C2 UAA201510327A UAA201510327A UA118192C2 UA 118192 C2 UA118192 C2 UA 118192C2 UA A201510327 A UAA201510327 A UA A201510327A UA A201510327 A UAA201510327 A UA A201510327A UA 118192 C2 UA118192 C2 UA 118192C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
glucan
beta
virus pharmaceutical
antiviral pharmaceutical
Prior art date
Application number
UAA201510327A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Юрій Захарович Толчеєв
Вадим Олексійович Козловський
Original Assignee
Юрій Захарович Толчеєв
Вадим Олексійович Козловський
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юрій Захарович Толчеєв, Вадим Олексійович Козловський filed Critical Юрій Захарович Толчеєв
Priority to UAA201510327A priority Critical patent/UA118192C2/en
Priority to PCT/UA2016/000122 priority patent/WO2017069721A1/en
Priority to EA201800266A priority patent/EA036809B1/en
Priority to RU2017125688A priority patent/RU2701514C2/en
Publication of UA118192C2 publication Critical patent/UA118192C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В изобретении раскрывается противовирусная фармацевтической композиция, содержащая бета-глюкан, преимущественно в виде карбоксиметил бета-глюкана натриевой соли, и йотта-каррагенан в весовом соотношении от приблизительно 1 к 0,5 до приблизительно 1 к 5. Противовирусная фармацевтическая композиция может быть представлена в виде аэрозоля для доставки посредством дозирующего ингалятора виде назального или вагинального спрея, в виде порошка для инсуффляций в полости тела или в виде геля.The invention discloses an antiviral pharmaceutical composition comprising beta-glucan, preferably in the form of sodium carboxymethyl beta-glucan and iotta-carrageenan in a weight ratio of from about 1 to 0.5 to about 1 to 5. The antiviral pharmaceutical composition may be presented as aerosol for delivery by means of a metered dose inhaler in the form of a nasal or vaginal spray, in the form of a powder for insufflation in the body cavity or in the form of a gel.

UAA201510327A 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION UA118192C2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
UAA201510327A UA118192C2 (en) 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION
PCT/UA2016/000122 WO2017069721A1 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition
EA201800266A EA036809B1 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition
RU2017125688A RU2701514C2 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201510327A UA118192C2 (en) 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
UA118192C2 true UA118192C2 (en) 2018-12-10

Family

ID=64604286

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201510327A UA118192C2 (en) 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION

Country Status (4)

Country Link
EA (1) EA036809B1 (en)
RU (1) RU2701514C2 (en)
UA (1) UA118192C2 (en)
WO (1) WO2017069721A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222581A1 (en) * 2017-05-29 2018-12-06 Resinnate Therapeutics Llc Methods and formulations for administering beta glucan
WO2018224589A1 (en) * 2017-06-07 2018-12-13 Nestec S.A. Powdered thickener maintaining its extensional properties when reconstituted and for promoting safe swallowing by individuals with dysphagia
WO2019185834A1 (en) 2018-03-29 2019-10-03 The Materia Company Limited Intravaginal formulation
SE546142C2 (en) * 2020-04-03 2024-06-11 Liw Innovation Ab New compositions for oral use
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1273576A (en) 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ITMI20032067A1 (en) 2003-10-23 2005-04-24 Unihart Corp SPRAY FORMULATION FOR THE TREATMENT OF VIRAL INFECTIONS.
US20060165623A1 (en) * 2005-01-24 2006-07-27 Terra Firma Natuals, Inc. Natural deodorant composition
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
DE602007005697D1 (en) * 2006-12-05 2010-05-12 Marinomed Biotechnologie Gmbh USE OF CARRAGEENAN FOR THE TREATMENT OF RHINOVIRUS INFECTIONS
IT1393272B1 (en) 2009-02-20 2012-04-12 D M G Italia S R L PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOSSIMETHYLBETHAGLAN FOR DISINFECTION OF NASAL MUCOSA AND ITS PREPARATION PROCEDURE

Also Published As

Publication number Publication date
RU2017125688A3 (en) 2019-01-23
WO2017069721A1 (en) 2017-04-27
RU2701514C2 (en) 2019-09-27
EA036809B1 (en) 2020-12-23
EA201800266A1 (en) 2018-09-28
RU2017125688A (en) 2019-01-23

Similar Documents

Publication Publication Date Title
UA118192C2 (en) ANTI-VIRUS PHARMACEUTICAL COMPOSITION
CY1120605T1 (en) DRY POWDER PREPARATION INCLUDING A PHOSPHODIESTERATION INHIBITOR
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
BR112016022598A8 (en) pharmaceutical aerosol composition in the form of a dry powder for pulmonary delivery, unit dosage form, pharmaceutical package, kit and use
MX2016015179A (en) A liquid formulation comprising nicotine for aerosol administration.
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
MX2015015132A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
MX2017003561A (en) Compositions and methods for cannabinoid coatings for use in drug delivery.
EP2682102A3 (en) Inhalation Compositions Comprising Corticosteroid and Sorbitol
WO2014007781A3 (en) Inhalation compositions
MX2018008646A (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
ZA202007890B (en) Stable pharmaceutical compositions for pressurized metered dose inhalers
MX2017013950A (en) Zolmitriptan powders for pulmonary delivery.
MX2015009891A (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
MX2015015150A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
BR112015022134A2 (en) compound, pharmaceutical composition, patch, stick, spray dispenser, tube or pen, and method of treating an infection
EA032975B1 (en) Pharmaceutical composition comprising a cyclic peptide of formula x-gqretpegaeakpwy-xand use for extracorporeal lung treatment
EA202091618A1 (en) COMPOSITION OF KETAMINE IN THE FORM OF A DRY POWDER FOR USE IN THE TREATMENT OF DEPRESSION BY INHALATION